DE69131629T2 - Behandlung fehlender milchabsonderung beim menschen - Google Patents

Behandlung fehlender milchabsonderung beim menschen

Info

Publication number
DE69131629T2
DE69131629T2 DE69131629T DE69131629T DE69131629T2 DE 69131629 T2 DE69131629 T2 DE 69131629T2 DE 69131629 T DE69131629 T DE 69131629T DE 69131629 T DE69131629 T DE 69131629T DE 69131629 T2 DE69131629 T2 DE 69131629T2
Authority
DE
Germany
Prior art keywords
people
higf
treatment
milk output
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69131629T
Other languages
English (en)
Other versions
DE69131629D1 (de
Inventor
Peter Gluckman
Stella Ruth Milsom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Publication of DE69131629D1 publication Critical patent/DE69131629D1/de
Application granted granted Critical
Publication of DE69131629T2 publication Critical patent/DE69131629T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
  • Treatment Of Sludge (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Dairy Products (AREA)
DE69131629T 1990-08-03 1991-07-19 Behandlung fehlender milchabsonderung beim menschen Expired - Fee Related DE69131629T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ23476690 1990-08-03
PCT/SE1991/000503 WO1992002245A1 (en) 1990-08-03 1991-07-19 Treatment of human lactation failure

Publications (2)

Publication Number Publication Date
DE69131629D1 DE69131629D1 (de) 1999-10-21
DE69131629T2 true DE69131629T2 (de) 2000-03-09

Family

ID=19923318

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69131629T Expired - Fee Related DE69131629T2 (de) 1990-08-03 1991-07-19 Behandlung fehlender milchabsonderung beim menschen

Country Status (13)

Country Link
US (1) US5276014A (de)
EP (1) EP0652767B1 (de)
JP (1) JP3074302B2 (de)
AT (1) ATE184489T1 (de)
AU (1) AU643073B2 (de)
CA (1) CA2086754C (de)
DE (1) DE69131629T2 (de)
DK (1) DK0652767T3 (de)
ES (1) ES2138960T3 (de)
GR (1) GR3032156T3 (de)
IE (1) IE912345A1 (de)
PT (1) PT98563B (de)
WO (1) WO1992002245A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243071A (en) * 1992-06-08 1994-09-27 Kabi Pharmacia Ab Igf-2 (or analogue) compositions for pharmaceutical uses
EP0739204A4 (de) * 1993-11-09 2000-03-15 Merck & Co Inc Piperidine, pyrrolidine und hexahydro-1h-azepine unterstützen die freisetzung des wachstumshormon
EP0776213A1 (de) * 1994-09-21 1997-06-04 Pharmacia & Upjohn Aktiebolag Verfahren für die behandlung von hypertonie in trächtigen säugetieren
US5858966A (en) * 1994-12-21 1999-01-12 Auckland Uniservices Limited Fetal growth
GR1007178B (el) * 1995-02-22 2011-01-31 Πετρομανωλακης Εμμ. Πρωραιος αγωγος σκαφους με διατομην αεροτομης.
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3853833A (en) * 1971-04-27 1974-12-10 Hormone Res Foundation Synthetic human growth-promoting and lactogenic hormones and method of producing same
BG49718A3 (en) * 1983-07-15 1992-01-15 Bio Technology General Corp Method for preparing of polypeptid with superoxiddismutasne activitty
EP0193917A3 (de) * 1985-03-06 1987-09-23 American Cyanamid Company Wasserdispersible und wasserlösliche Polymerzusammensetzungen für parenterale Anwendung
AU6104686A (en) * 1985-08-12 1987-02-19 Syntex (U.S.A.) Inc. Bovine growth hormone releasing factor perivative
US4783524A (en) * 1985-09-17 1988-11-08 Monsanto Company Growth factors
CA1299103C (en) * 1986-03-07 1992-04-21 Robert Joseph Collier Method and compositions for increasing mammary parenchyma
IL86102A (en) * 1987-05-11 1994-04-12 Univ Tulane Alkylated peptides that release growth hormone and their use
FR2622455B1 (fr) * 1987-11-04 1991-07-12 Agronomique Inst Nat Rech Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5089473A (en) * 1988-08-29 1992-02-18 Monsanto Company Somatotropin variants and their use

Also Published As

Publication number Publication date
PT98563B (pt) 1999-01-29
ES2138960T3 (es) 2000-02-01
DE69131629D1 (de) 1999-10-21
DK0652767T3 (da) 2000-04-03
CA2086754C (en) 2000-08-29
AU643073B2 (en) 1993-11-04
EP0652767B1 (de) 1999-09-15
EP0652767A1 (de) 1995-05-17
JP3074302B2 (ja) 2000-08-07
JPH05509329A (ja) 1993-12-22
ATE184489T1 (de) 1999-10-15
WO1992002245A1 (en) 1992-02-20
IE912345A1 (en) 1992-02-12
GR3032156T3 (en) 2000-04-27
PT98563A (pt) 1992-06-30
US5276014A (en) 1994-01-04
CA2086754A1 (en) 1992-02-04
AU8510891A (en) 1992-03-02

Similar Documents

Publication Publication Date Title
CA2285203A1 (en) Compositions containing capsaicin or capsaicin analogues and a local anesthetic
ATE203165T1 (de) Behandlung des partiellen wachstumshormon- unempfindlichkeitssyndromes
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
HUT51136A (en) Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component
GR3032037T3 (en) Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
HU9700654D0 (en) Antitussive compositions
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
DE69800859T2 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
DE69131629D1 (de) Behandlung fehlender milchabsonderung beim menschen
DE3880587T2 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE3879489D1 (de) Pharmazeutische kompositionen zum behandeln von adrenoleukodystrophie.
RU96111879A (ru) Способ приготовления гомеопатических мягких лекарственных форм
RU94017682A (ru) Способ добычи и изготовления лекарственной формы прополиса
HU190667B (en) Process for producing solution for stimulating regeneration of living tissues

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee